Core Viewpoint - Bank of America Securities has raised the target price for Kelun-Biotech from HKD 471.5 to HKD 522, maintaining a "Neutral" rating, citing encouraging clinical progress but limited short-term authorization opportunities [1] Clinical Progress - The report highlights significant improvements in progression-free survival (PFS) data for sac-TMT and A166, which contributed to the upward revision of the target price [1] - The National Medical Products Administration has recently approved sac-TMT for second-line treatment of EGFR mutation non-small cell lung cancer (NSCLC) and A166 for second-line and above HER2-positive breast cancer (BC) [1] Revenue Forecast - Revenue forecasts for 2025 to 2027 have been increased by 1% to 5%, reflecting the positive clinical developments and long-term projections [1]
大行评级丨美银：上调科伦博泰生物目标价至522港元 重申“中性”评级